Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The COVID-19 infection primarily manifests itself as a respiratory tract infection, although
new evidence indicates that this disease has systemic involvement involving multiple systems
including the cardiovascular, respiratory, gastrointestinal, neurological, hematopoietic and
immune systems. Recent studies have shown that in its pathophysiology, inflammation and
thrombogenesis predominate, especially in the severe forms of COVID-19. Thus, the
investigators hypothesized that the use of heparin and tocilizumab could potencially reduce
inflammation and thrombogenesis in patients with severe COVID-19 infection, improving
patients outcomes and survival.
Phase:
Phase 3
Details
Lead Sponsor:
University of Sao Paulo
Collaborator:
Conselho Nacional de Desenvolvimento Científico e Tecnológico